Novartis challenges Glaxo patent
Swiss-based Novartis AG said on Friday that its Geneva Pharmaceuticals generic drug unit had challenged GlaxoSmith-Kline Plc's US patents on Augmenting, the world's biggest-selling antibiotic.
Swiss-based Novartis AG said on Friday that its Geneva Pharmaceuticals generic drug unit had challenged GlaxoSmith-Kline Plc's US patents on Augmenting, the world's biggest-selling antibiotic.